Evidence map›Paper›PMID 42099344›Full record

ReviewCureus2026

Long-Term Outcomes After Guillain-Barré Syndrome: A Systematic Review of Functional Recovery, Residual Symptoms, and Quality of Life.

Sharafath Hussain Zahir Hussain, Zaw Moe

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sharafath Hussain Zahir HussainInternal Medicine, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, GBR.
Zaw MoeNeurology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy characterized by rapidly progressive weakness and variable recovery trajectories. Although many patients regain functional independence after the acute phase, increasing evidence suggests that long-term sequelae such as fatigue, pain, residual disability, and reduced health-related quality of life are common and frequently under-recognized. However, contemporary evidence on long-term outcomes after GBS remains dispersed across multiple study designs and populations, making an updated synthesis clinically relevant. This systematic review aimed to evaluate long-term outcomes reported at or beyond six months after GBS onset, focusing on functional recovery, persistent symptoms, and patient-reported quality of life. A systematic search of PubMed was conducted for studies published between January 2014 and November 2025 using predefined search terms related to GBS and long-term outcomes. Studies reporting outcomes beyond six months after disease onset were included, encompassing cohort studies, clinical trials with follow-up, qualitative studies, and systematic reviews. Due to heterogeneity in study design, outcome measures, and follow-up duration, findings were synthesized narratively. Across the included literature, most patients demonstrated substantial neurological recovery within the first year; however, a clinically meaningful proportion continued to experience persistent symptoms beyond one to three years. Fatigue and neuropathic pain were among the most frequently reported long-term sequelae and were major contributors to impaired quality of life despite apparent motor recovery. Residual functional limitations, participation restrictions, and psychosocial impacts were also commonly reported. Factors associated with poorer long-term outcomes included older age, severe disease at presentation, requirement for mechanical ventilation, autonomic dysfunction, and axonal electrophysiological patterns. These findings highlight that recovery from GBS is often incomplete despite improvement in neurological function. Long-term follow-up incorporating rehabilitation, symptom-directed management, and patient-reported outcome measures may be essential to better address persistent morbidity and optimize quality of life in GBS survivors.

Indexed as

all neurologyguillain-barré syndromenarrative reviewquality of lifereview articlesystematic review

Identifiers

PMID42099344
PMCPMC13147904

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.